In this sense, epidemiological studies have demonstrated an increase in plasma levels of inflammatory markers such as CRP, IL-6 and TNF-α in patients with metabolic syndrome and also in those with clinically overt T2D [2,3]. This evidence concerns the gene CRP and type 2 diabetes mellitus.